Summary
- Morphic intends to raise $75 million from the sale of its common stock in an IPO.
- The firm is an ultra-early-stage company advancing a pipeline of treatments for various diseases.
- While its technologies are promising, MORF's IPO is likely more suitable for very long-term hold institutional investors.
- Looking for a community to discuss ideas with? IPO Edge features a chat room of like-minded investors sharing investing ideas and strategies. Start your free trial today »
Quick Take
Morphic Holding (MORF) has filed to raise gross proceeds of $75 million from a U.S. IPO, according to an S-1/A registration statement.
The firm is developing oral small-molecule integrin therapeutics for immunological, fibrotic, neoplastic and vascular diseases.
MORF has not yet entered Phase 1 trials, so the IPO is probably more suited to long-term hold institutional investors.
